NASDAQ:CUE - Cue Biopharma Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$6.19 +0.07 (+1.14 %)
(As of 11/13/2018 01:12 PM ET)
Previous Close$6.12
Today's Range$6.13 - $6.36
52-Week Range$5.90 - $17.99
Volume1,319 shs
Average Volume109,151 shs
Market Capitalization$143.95 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Cue Biopharma, Inc., a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers and autoimmune disorders. The company's lead drug candidate includes CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to human papilloma virus related cancers. Its biologics drug candidates also comprise CUE-100 series to improve various tumor specific T cells; and CUE-200 series to reinvigorate exhausted T cells. The company also offers MOD costimulatory optimization and discovery platform and viraTope T cell epitope discovery platform to develop novel biologics for addressing new indications in oncology and autoimmune disorders. Cue Biopharma, Inc. has a collaboration agreement with Merck & Co. for the research and development of its proprietary biologics that target autoimmune disease indications. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is based in Cambridge, Massachusetts.

Receive CUE News and Ratings via Email

Sign-up to receive the latest news and ratings for CUE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CUE
Previous Symbol
CUSIPN/A
Phone781-305-7777

Debt

Debt-to-Equity RatioN/A
Current Ratio16.64
Quick Ratio16.64

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.17 per share
Price / Book1.95

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees30
Outstanding Shares20,130,000
Market Cap$143.95 million
OptionableNot Optionable

Cue Biopharma (NASDAQ:CUE) Frequently Asked Questions

What is Cue Biopharma's stock symbol?

Cue Biopharma trades on the NASDAQ under the ticker symbol "CUE."

How were Cue Biopharma's earnings last quarter?

Cue Biopharma Inc (NASDAQ:CUE) posted its quarterly earnings results on Monday, May, 14th. The company reported ($0.37) EPS for the quarter. View Cue Biopharma's Earnings History.

What price target have analysts set for CUE?

1 brokerages have issued 1 year target prices for Cue Biopharma's stock. Their predictions range from $14.50 to $14.50. On average, they anticipate Cue Biopharma's stock price to reach $14.50 in the next year. This suggests a possible upside of 134.2% from the stock's current price. View Analyst Price Targets for Cue Biopharma.

What is the consensus analysts' recommendation for Cue Biopharma?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cue Biopharma in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cue Biopharma.

Has Cue Biopharma been receiving favorable news coverage?

News articles about CUE stock have trended somewhat positive on Tuesday, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cue Biopharma earned a news impact score of 0.9 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near future.

Who are some of Cue Biopharma's key competitors?

Who are Cue Biopharma's key executives?

Cue Biopharma's management team includes the folowing people:
  • Mr. Daniel R. Passeri M.Sc., MSc., J.D., CEO, Pres & Director (Age 57)
  • Mr. Colin G. Sandercock J.D., M.Sc., Sr. VP, Gen. Counsel & Sec. (Age 61)
  • Dr. Ronald D. Seidel III, Exec. VP and Head of R&D (Age 42)
  • Dr. Rodolfo J. Chaparro, Exec. VP & Head of Immunology (Age 45)
  • Dr. Steven C. Almo, Founder and Chairman of Scientific & Clinical Advisory Board (Age 57)

Who are Cue Biopharma's major shareholders?

Cue Biopharma's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.51%) and P.A.W. Capital Corp (0.40%). Company insiders that own Cue Biopharma stock include Daniel R Passeri and Kerri-Ann Millar. View Institutional Ownership Trends for Cue Biopharma.

Which institutional investors are buying Cue Biopharma stock?

CUE stock was purchased by a variety of institutional investors in the last quarter, including P.A.W. Capital Corp and BlackRock Inc.. Company insiders that have bought Cue Biopharma stock in the last two years include Daniel R Passeri and Kerri-Ann Millar. View Insider Buying and Selling for Cue Biopharma.

How do I buy shares of Cue Biopharma?

Shares of CUE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cue Biopharma's stock price today?

One share of CUE stock can currently be purchased for approximately $6.19.

How big of a company is Cue Biopharma?

Cue Biopharma has a market capitalization of $143.95 million. Cue Biopharma employs 30 workers across the globe.

What is Cue Biopharma's official website?

The official website for Cue Biopharma is http://www.cuebiopharma.com.

How can I contact Cue Biopharma?

Cue Biopharma's mailing address is 21 ERIE STREET, CAMBRIDGE MA, 02139. The company can be reached via phone at 781-305-7777.


MarketBeat Community Rating for Cue Biopharma (NASDAQ CUE)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  47 (Vote Outperform)
Underperform Votes:  70 (Vote Underperform)
Total Votes:  117
MarketBeat's community ratings are surveys of what our community members think about Cue Biopharma and other stocks. Vote "Outperform" if you believe CUE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CUE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/13/2018 by MarketBeat.com Staff

Featured Article: Reverse Stock Split

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel